The incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing over the past few decades and survival rates for patients with this malignancy remain dismal. The authors of this Perspective discuss the challenges that have limited progress in the development of treatments for patients with PDAC and present novel approaches that could be leveraged to improve their outcomes.
- Stephan B. Dreyer
- Philip Beer
- Andrew V. Biankin